- 1D
- 1W
- 1M
- 1Y
- 5Y
- YTD
About Tarsus Pharmaceuticals
Tarsus Pharmaceuticals Inc. is a late clinical-stage biopharmaceutical company. The Company if focused on the development and commercialization of therapeutic candidates to address ophthalmic conditions. Its lead product candidate, TP-03, is a novel therapeutic being developed for the treatment of blepharitis caused by the infestation of Demodex mites (Demodex blepharitis). It is developing TP-03 as an eye drop. It is also focused on developing additional clinical-stage product candidates, including TP-04 and TP-05. TP-04 is being developed for the treatment of rosacea and TP-05 for Lyme prophylaxis and community malaria reduction.
0.53%
2.88%
News
Connect
People who are active on baraka tribe community
Stock Analysis
last close
$28.42
1-mo return
32.5%
3-mo return
11.5%
avg daily vol.
33.53T
52-week high
63.69
52-week low
17.96
market cap.
$587M
forward pe
-
annual div.
-
roe
-5.5%
ltg forecast
-
dividend yield
-
annual rev.
$55M
inst own.
63.8%
